Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Somatostatinoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Mesothelioma, Malignant 2Insulinoma 2Glucagonoma 2Gliosarcoma 2Gastrinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Islet Cell 2Brain Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1

Interventions

Octreotide 4Leucovorin 3Trastuzumab 2Temozolomide 2Oxaliplatin 2Fluorouracil 2Capecitabine 2Bevacizumab 2veliparib 1vatalanib 1tipifarnib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Salts 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vipoma × vatalanib × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡